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Macrolide Derivatives Reduce Proinflammatory Macrophage Activation and 
Macrophage‐Mediated Neurotoxicity 
Abstract 
Introduction: Azithromycin (AZM) and other macrolide antibiotics are applied as immunomodulatory 
treatments for CNS disorders. The immunomodulatory and antibiotic properties of AZM are purportedly 
independent. 
Aims: To improve the efficacy and reduce antibiotic resistance risk of AZM‐based therapies, we evaluated 
the immunomodulatory and neuroprotective properties of novel AZM derivatives. We semisynthetically 
prepared derivatives by altering sugar moieties established as important for inhibiting bacterial protein 
synthesis. Bone marrow‐derived macrophages (BMDMs) were stimulated in vitro with proinflammatory, 
M1, stimuli (LPS + INF‐gamma) with and without derivative costimulation. Pro‐ and anti‐inflammatory 
cytokine production, IL‐12 and IL‐10, respectively, was quantified using ELISA. Neuron culture treatment 
with BMDM supernatant was used to assess derivative neuroprotective potential. 
Results: Azithromycin and some derivatives increased IL‐10 and reduced IL‐12 production of M1 
macrophages. IL‐10/IL‐12 cytokine shifts closely correlated with the ability of AZM and derivatives to 
mitigate macrophage neurotoxicity. 
Conclusions: Sugar moieties that bind bacterial ribosomal complexes can be modified in a manner that 
retains AZM immunomodulation and neuroprotection. Since the effects of BMDMs in vitro are predictive 
of CNS macrophage responses, our results open new therapeutic avenues for managing maladaptive 
CNS inflammation and support utilization of IL‐10/12 cytokine profiles as indicators of macrophage 
polarization and neurotoxicity. 
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1  | INTRODUC TION
The management of maladaptive inflammation is an emerging ther‐
apeutic target for many neuropathologies. Different macrophage 
phenotypes have been identified in the injured central nervous 
system (CNS) in conditions such as ischemic brain damage, spinal 
cord injury, and traumatic brain injury. After spinal cord injury, for 
example, there is a heterogeneous neuroinflammatory response me‐
diated by resident microglia and infiltrating macrophages. Classically 
activated macrophages (M1) secrete proinflammatory cytokines and 
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Summary
Introduction: Azithromycin (AZM) and other macrolide antibiotics are applied as im‐
munomodulatory treatments for CNS disorders. The immunomodulatory and antibi‐
otic properties of AZM are purportedly independent.
Aims: To improve the efficacy and reduce antibiotic resistance risk of AZM‐based 
therapies, we evaluated the immunomodulatory and neuroprotective properties of 
novel AZM derivatives. We semisynthetically prepared derivatives by altering sugar 
moieties established as important for inhibiting bacterial protein synthesis. Bone mar‐
row‐derived macrophages (BMDMs) were stimulated in vitro with proinflammatory, 
M1, stimuli (LPS + INF‐gamma) with and without derivative costimulation. Pro‐ and 
anti‐inflammatory cytokine production, IL‐12 and IL‐10, respectively, was quantified 
using ELISA. Neuron culture treatment with BMDM supernatant was used to assess 
derivative neuroprotective potential.
Results: Azithromycin and some derivatives increased IL‐10 and reduced IL‐12 pro‐
duction of M1 macrophages. IL‐10/IL‐12 cytokine shifts closely correlated with the 
ability of AZM and derivatives to mitigate macrophage neurotoxicity.
Conclusions: Sugar moieties that bind bacterial ribosomal complexes can be modi‐
fied in a manner that retains AZM immunomodulation and neuroprotection. Since 
the effects of BMDMs in vitro are predictive of CNS macrophage responses, our re‐
sults open new therapeutic avenues for managing maladaptive CNS inflammation 
and support utilization of IL‐10/12 cytokine profiles as indicators of macrophage po‐
larization and neurotoxicity.
K E Y W O R D S
brain, erythromycin, M2, microglia, spinal cord injury, stroke
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chemokines and contribute to continued cell death and a persistent 
inflammatory microenvironment within the injured spinal cord.1,2 In 
contrast, alternatively activated macrophages (M2) release anti‐in‐
flammatory cytokines and facilitate tissue repair.2 Increasingly, cli‐
nicians and researcher are testing the therapeutic potential of drugs 
that polarize macrophage activation toward reparative phenotypes 
in a variety of CNS disorders.
Macrolide antibiotics are a class of natural products consisting of 
a highly substituted macrocyclic 14‐, 15‐, or 16‐membered lactone 
ring. Azithromycin (AZM) is a 15‐membered, second generation, 
synthetic derivative of erythromycin with improved pharmacoki‐
netic properties and a broad antimicrobial spectrum.3 Azithromycin 
is well tolerated and commonly prescribed. Moreover, AZM be‐
comes highly concentrated in macrophages and other phagocytes.4,5 
Across a variety of inflammatory conditions, AZM attenuates proin‐
flammatory cytokine production by macrophages and other immune 
cells.6
Azithromycin and other macrolide antibiotics are now 
being tested as immunomodulatory agents for CNS disorders. 
Specifically, we and others observed immunomodulatory effects 
and improved recovery with AZM treatment in spinal cord injury, 
stroke, and retinal ischemia/reperfusion injury.7-12 The neuropro‐
tective properties of AZM in these models are associated with 
direct effects on macrophages.7-9 We have shown that in vitro 
application of AZM to proinflammatory M1 bone marrow‐derived 
macrophages (BMDMs) dampens the release of proinflammatory 
cytokines, increases M2‐associated anti‐inflammatory cytokines, 
and reduces the neurotoxicity of M1 macrophage‐conditioned 
medium.7
In efforts to improve efficacy and/or reduce the risk of in‐
creasing antibiotic resistance, researchers are evaluating the 
immunomodulatory potential of AZM derivatives and other mac‐
rolide derivatives with the goal of separating the antibiotic from 
immunomodulatory properties. As a result, some macrolide de‐
rivatives have been shown to retain immunomodulatory proper‐
ties in models of lung inflammation, inflammatory bowel diseases, 
arthritis, and skin inflammation.13‐18 The ability of macrolide de‐
rivatives to reduce macrophage‐mediated neurotoxicity, however, 
is unknown. With the increased use of AZM as an immunomod‐
ulatory agent for macrophage‐mediated neurotoxicity in CNS pa‐
thologies, our goal in the present study was to determine whether 
macrolide derivatives retain neuroprotective properties. Using a 
semisynthetic approach to target modification of the sugar moi‐
eties of AZM, we generated a small library of derivatives, some of 
which lacked the cladinose found in the parent. We then tested 
the cytokine profiles and neurotoxicity of M1‐stimulated BMDMs 
treated with derivatives and observed that unique derivatives re‐
duce M1‐macrophage activation and subsequent neuron death. 
Previously we determined that the effect of BMDMs in vitro is 
predictive of macrophage responses in the injured CNS8,19,20; 
therefore, the results of the current study open new therapeutic 
avenues for the management of maladaptive inflammation in CNS 
disorders.
2  | METHODS
2.1 | Semisynthesis of AZM derivatives
Like other macrolides, AZM inhibits bacterial protein synthesis by 
binding to the 50S subunit of ribosome and thus interfering with 
the growth of the polypeptide chain.21,22 Specifically, the sugar 
moieties are known to play an essential role in establishing bind‐
ing interactions with the bacterial ribosomal assembly. We used a 
semisynthetic approach to create derivatives with targeted altera‐
tions in these bacterial binding sugar residues. The AZM derivatives 
that were synthesized and structurally confirmed by spectroscopic 
analysis are listed in Table 1. See Supporting information for mass 
and H NMR spectrum profiles.
AZM 1: The removal of the cladinose of AZM followed a previously 
described procedure.23	 Briefly,	 AZM	 (6.67	mmol)	 was	 dissolved	 into	
200 mL of methanol containing 1% of conc. HCl, and the solution was 
stirred at room temperature for 24 hours Saturated NaHCO3 solution 
was added to neutralilze the solution, and the solvent was removed 
under vacuum. The product was purified by flash column chromatogra‐
phy with silica gel (EtOAc/MeOH) to give AZM1 (5.53 mmol). MS (ESI) 
m/z: [M + H]+ calcd for C30H59N2O9 591.4; found 591.4.
AZM4: AZM1 (4.00 mmol) was dissolved into 100 mL anhydrous 
ethyl	acetate.	Acetic	anhydride	(3.67	mL,	40.0	mmol)	was	added,	and	
the solution was stirred for 2 hours at room temperature. The mix‐
ture was washed twice with NaHCO3 (5% in water, 30 mL), and the 
organic phase was dried under vacuum. The product was purified by 
flash column chromatography with silica gel (DCM/MeOH) to give 
AZM2 (3.22 mmol). AZM2 (2.0 mmol) was dissolved into 40 mL an‐
hydrous acetone solution on ice, and 2.0 mL Jones reagent was added 
dropwise. After 30 minutes, 10 mL of methanol and 10 mL saturated 
NaHCO3 solutions were added and the solid precipitate was col‐
lected by filtration and dried under vacuum. The product was puri‐
fied by flash column chromatography with silica gel (DCM/MeOH) to 
give AZM3 (1.30 mmol). AZM3 (1.0 mmol) was dissolved into 30 mL 
methanol, and sodium methoxide (5.0 mmol) with 5 mL of water was 
added. The solution was stirred at room temperature for 3 hours, and 
the solvent was removed under vacuum. The product was purified 
by flash column chromatography with silica gel (DCM/MeOH) to 
give	0.44	g	AZM4	(0.75	mmol).	1H NMR (400 MHz, Methanol‐d4) δ 
5.47	(s,	1H),	4.98	(dd,	J = 9.8, 3.0 Hz, 1H), 4.16 (d, J	=	7.4	Hz,	1H),	3.78	
(d, J = 9.9 Hz, 1H), 3.65 (s, 1H), 3.55 (ddd, J = 11.0, 6.1, 1.9 Hz, 2H), 
3.30‐3.23 (m, 1H), 3.02 (d, J	=	12.3	Hz,	1H),	2.79	(q,	J	=	7.1	Hz,	1H),	
2.60 (ddd, J = 12.2, 10.2, 4.2 Hz, 1H), 2.32 (s, 6H), 2.22 (d, J = 2.2 Hz, 
3H), 2.20 (d, J = 2.9 Hz, 1H), 1.98 (d, J = 10.6 Hz, 1H), 1.85 (ddd, 
J	=	11.5,	7.5,	3.9	Hz,	3H),	1.72	 (ddd,	J = 12.8, 4.2, 2.0 Hz, 2H), 1.46 
(d, J	=	14.7	Hz,	1H),	1.37	(s,	3H),	1.33-1.26	(m,	2H),	1.24	(d,	J = 4.5 Hz, 
1H), 1.19 (td, J	=	10.5,	10.1,	7.2	Hz,	9H),	1.07	(d,	J	=	6.7	Hz,	5H),	1.00	
(d, J	=	6.6	Hz,	3H),	0.87	(dd,	J = 8.4, 6.5 Hz, 3H). 13C NMR (101 MHz, 
Methanol‐d4) δ	174.43,	106.50,	104.20,	93.68,	82.68,	70.25,	68.82,	
64.29,	64.17,	61.12,	53.40,	48.44,	45.18,	43.74,	39.56,	30.86,	28.80,	
25.39,	20.08,	20.04,	16.14,	15.22,	11.01,	10.87,	9.78,	9.42,	7.46.	MS	
(ESI) m/z: [M + H]+ calcd for C30H57N2O9 589.4; found 589.4.
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TA B L E  1   Structure, molecular weight, and antibiotic properties of derivatives
Derivatives name Structure Molecular weight MICa (μmol/L)
AZM (parent compound)
O
N
OH
HO
O O
OH
O O
N
HO
O
OCH3
OH
748.51 1.0
AZM1
O
N
OH
HO
O OH
OH
O O
NH
HO
590.79 1000
AZM4
O
N
OH
HO
O O
OH
O O
N
HO
588.77 500
AZM5
O
N
OH
HO
O O
OH
O O
NAcO
O
OCH3
OAc
833.06 2.0
(Continues)
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AZM5: AZM (2.0 mmol) was dissolved into 50 mL anhydrous 
dimethylene chloride. Acetic anhydride (1.88 mL, 20.0 mmol) was 
added, and the solution was stirred for 1 hour The mixture was 
washed twice with NaHCO3 (5% in water, 30 mL), and the organic 
phase was dried under vacuum. The product was purified by flash 
column chromatography with silica gel (EtOAc/MeOH) to give 1.16 g 
AZM5 (1.39 mmol). 1H NMR (400 MHz, Methanol‐d4) δ 5.48 (s, 
0H), 5.09 (d, J	=	4.7	Hz,	1H),	5.00	(dd,	J	=	10.4,	2.5	Hz,	1H),	4.97	(d,	
J	=	4.7	Hz,	1H),	4.71	(d,	J = 4.3 Hz, 1H), 4.69‐4.61 (m, 2H), 4.42‐4.30 
(m, 2H), 4.16 (dd, J = 5.0, 1.9 Hz, 1H), 4.10 (dd, J = 6.8, 2.5 Hz, 1H), 
3.94-3.77	(m,	2H),	3.62	(dd,	J = 6.4, 3.1 Hz, 1H), 3.59 (d, J = 1.9 Hz, 
1H), 3.42 (ddd, J	=	10.7,	 7.2,	 3.6	Hz,	 1H),	 3.36	 (d,	 J = 10.2 Hz, 3H), 
3.27-3.14	 (m,	 2H),	 2.96-2.89	 (m,	 1H),	 2.89-2.82	 (m,	 1H),	 2.73	 (d,	
J = 3.5 Hz, 6H), 2.49 (d, J = 15.3 Hz, 1H), 2.08 (s, 3H), 2.05‐1.95 (m, 
3H), 1.89 (s, 6H), 1.84 (ddd, J	=	7.9,	6.0,	2.3	Hz,	1H),	1.79-1.63	 (m,	
3H), 1.56‐1.40 (m, 4H), 1.34 (d, J = 29.4 Hz, 3H), 1.28‐1.20 (m, 9H), 
1.16 (t, J	=	6.6	Hz,	 3H),	 1.14-1.09	 (m,	 6H),	 1.07	 (d,	 J	=	7.5	Hz,	 3H),	
0.99 (dd, J	=	13.7,	 6.9	Hz,	 3H),	 0.88	 (q,	 J	=	7.5	Hz,	 3H).	 13C NMR 
(101 MHz, Methanol‐d4) δ	178.13,	170.68,	170.67,	101.68,	101.59,	
96.21,	95.13,	76.53,	74.67,	74.56,	74.24,	73.79,	72.99,	72.95,	69.64,	
67.15,	66.73,	65.33,	65.12,	64.63,	63.05,	62.94,	48.75,	48.73,	45.13,	
41.78,	38.72,	35.52,	30.25,	25.45,	25.31,	22.41,	20.73,	20.58,	20.35,	
20.14,	19.44,	19.39,	17.08,	16.96,	15.96,	14.10,	10.09,	10.08.	MS	(ESI)	
m/z: [M + H]+ calcd for C42H77N2O14 834.5, found 834.5.
AZM7:	AZM	 (2.0	mmol)	was	 dissolved	 into	 80	mL	 anhydrous	
ethyl	 acetate.	3.76	mL	 (40.0	mmol)	of	acetic	anhydride	and	4-di‐
methylaminopyridine (0.20 mmol) were added. After stirring at 
room temperature for 12 hours, the mixture was washed twice 
with NaHCO3 (5% in water, 30 mL), and the organic phase was 
dried under vacuum. The product was purified by flash column 
chromatography with silica gel (DCM/MeOH) to give AZM6 
(1.64 mmol). AZM6 (1.0 mmol) was dissolved into 40 mL of meth‐
anol containing 1% of conc. HCl, and the solution was stirred at 
room temperature for 16 hours Saturated NaHCO3 solution was 
added to neutralilze the solution, and the solvent was removed 
under vacuum. The product was purified by flash column chro‐
matography	on	silica	gel	(EtOAc/MeOH)	to	give	0.34	g	AZM7.	1H 
NMR (400 MHz, Chloroform‐d) δ 4.96 (d, J = 5.6 Hz, 1H), 4.85 (dd, 
J	=	10.6,	2.6	Hz,	1H),	4.79	(dd,	J	=	10.5,	7.6	Hz,	1H),	4.75-4.67	(m,	
1H), 4.62‐4.55 (m, 1H), 4.45 (dd, J	=	9.7,	2.0	Hz,	1H),	3.88	(s,	1H),	
3.66 (d, J = 2.1 Hz, 1H), 3.60‐3.52 (m, 2H), 3.22 (s, 3H), 3.18 (s, 
1H), 2.94 (t, J = 9.6 Hz, 1H), 2.69 (dddt, J = 14.3, 11.0, 6.9, 3.9 Hz, 
2H),	2.57	(t,	J	=	7.1	Hz,	1H),	2.37	(s,	1H),	2.23	(s,	6H),	2.09	(s,	3H),	
2.06	 (s,	 3H),	 2.02	 (s,	 3H),	 1.82-1.76	 (m,	 2H),	 1.76-1.68	 (m,	 2H),	
1.38‐1.31 (m, 2H), 1.30‐1.24 (m, 6H), 1.24‐1.20 (m, 6H), 1.19 (d, 
J = 5.2 Hz, 4H), 0.98 (d, J	=	6.7	Hz,	 3H),	 0.94	 (d,	 J = 6.9 Hz, 2H), 
0.91 (d, J	=	7.2	Hz,	2H),	0.85	(t,	J	=	7.4	Hz,	3H).	13C NMR (101 MHz, 
Chloroform‐d) δ	 169.96,	 109.99,	 101.25,	 99.81,	 98.81,	 97.54,	
78.04,	 76.36,	 75.46,	 74.90,	 73.96,	 71.46,	 70.85,	 69.36,	 64.44,	
63.32,	 60.36,	 56.28,	 49.01,	 40.63,	 37.75,	 30.45,	 26.15,	 25.29,	
21.37,	 21.11,	 21.01,	 20.96,	 20.91,	 20.43,	 18.17,	 14.16.	MS	 (ESI)	
m/z: [M + H]+ calcd for C34H63N2O11	675.4,	found	675.4.
2.2 | Antibiotic activity
The minimum inhibitory concentration (MIC) displays the relative 
antibiotic potency of AZM and each derivative against a common 
strain of bacteria (Staphylococcus aureus). The protocol used for the 
determination of the MIC was as previously described with minor 
modifications.24 Staphylococcus aureus subsp aureus Rosenbach 
(ATCC 6538) were grown in 5 mL of BactoTM Tryptic Soy Broth me‐
dium	for	16	hours	at	37°C	with	shaking	(250	rpm)	when	an	aliquot	
was diluted X1000 into 4.5 mL of fresh medium and incubated until 
OD600 reaching 0.4. An aliquot of the suspension was diluted X1000. 
An aliquot (90 μL) was transferred into an individual well of a 96‐
well plate supplied with 5 μL of the test compound or control (AZM). 
Maximum final concentration of 1000 μmol/L with serial dilutions 
was used to measure the antistaphylococcal activity in comparison 
with the negative control (1% DMSO). The culture plates were in‐
cubated	at	37°C	for	16	hours	with	shaking	 (50	rpm).	The	OD600 of 
each well measured using BioTek™ Synergy™ (Biotek, Winooski, VT) 
2 Multi‐Mode Microplate Readers. The acquired OD600 values were 
normalized to the negative control wells (100% viability). Resazurin 
solution (5 μL) was also added to each well, and the plates were 
shaken	 for	10	seconds	and	 incubated	at	37°C	 for	 another	3	hours	
to allow resazurin to convert to resorufin by viable bacteria. The 
minimal concentration of the tested compound that caused growth 
inhibition was recorded. The calculated MICs are shown in Table 1.
Derivatives name Structure Molecular weight MICa (μmol/L)
AZM7
O
N
OAc
HO
O OH
OH
O O
NAcO
674.44 1000
aMinimum inhibitory concentration against Staphylococcus aureus subsp aureus Rosenbach (ATCC 6538). 
TA B L E  1   (Continued)
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2.3 | Preparation of bone marrow‐derived 
macrophages (BMDMs) and macrophage‐conditioned 
medium (MCM)
BMDMs	were	isolated	from	the	femurs	and	tibias	of	C57BL/6	mice	
at 10‐16 weeks of age. In a tissue culture hood, the bones were 
flushed with a syringe filled with cold washing media (RPMI 1640 
supplemented with 10% FBS and 1% penicillin/streptomycin) to ex‐
trude bone marrow into a sterile falcon tube. The bone marrow was 
then triturated three times using syringes fit with 18 gauge needles 
and	then	centrifuged	at	1000	rpm	for	5	minutes	at	4°C.	After	remov‐
ing supernatant, red blood cells were lysed in lysis buffer (0.15 mol/L 
NH4Cl,	10	mmol/L	KHCO3,	and	0.1	mmol/L	Na2EDTA,	pH	7.4)	for	
3 min. The remaining cells were washed once in washing media and 
then centrifuged at 212 g	 for	 5	minutes	 at	 4°C.	 The	 resulting	 cell	
pellet was resuspended in BMDM culture media (RPMI 1640 supple‐
mented with 1% penicillin/streptomycin, 1% HEPES, 0.001% β‐mer‐
captoethanol, 10% FBS, and 20% supernatant from sL929 cells) and 
then	plated	in	T75	flasks	at	a	density	of	1	×	106 cells/mL. The sL929 
cell supernatant (cells, a generous gift from Phillip Popovich at The 
Ohio State University) contains macrophage colony stimulating fac‐
tor, which is needed to promote differentiation of bone marrow cells 
into macrophages.25 Cell culture media was changed on days 2, 4, 
and	6,	and	then,	cells	were	replated	at	the	density	of	1	×	106 cells/mL 
on	day	7	for	designated	stimulation	and/or	azithromycin	(AZM)	treat‐
ment. The following day, BMDMs were stimulated to be M1 using 
LPS (50 ng/mL; Invivogen) plus IFN‐gamma (20 ng/mL; eBioscience) 
diluted in N2A growth medium as previously described.7 AZM (Sigma 
PHR1088) or AZM derivatives were diluted to the concentrations of 
1, 5, 25, and 125 μmol/L and then added to the BMDMs at the time 
of stimulation. Unstimulated BMDMs maintained in N2A growth 
medium were used as control. Six hours following incubation, the su‐
pernatant of the stimulated macrophages (macrophage‐conditioned 
media (MCM)) was collected and centrifuged to remove the cell de‐
bris. The resulting media was either applied to Neuro‐2a cells for the 
measurement of neurotoxicity or tested for IL‐10 and IL‐12p40 levels 
using standard ELISA kits (Thermo Scientific, Rockford, IL).
2.4 | Assessment of macrophage and neuron 
cell viability
BMDMs	 seeded	 in	 96-well	 plates	 (1	×	106 cells/mL) were treated 
with a range of concentrations (1‐125 μmol/L) of AZM or AZM de‐
rivatives for 24 hours Neuro2a (N2a) cell line is a generous gift from 
Chris Richards at the University of Kentucky. Cells were cultured in 
N2a growth media, which contains 45% DMEM and 45% Opti‐MEM 
Reduced‐Serum Medium (Life Technologies) supplemented with 
10% FBS and 1% penicillin/streptomycin.26 Experiments were car‐
ried out using N2a cells within 12 passages. To test the neurotoxic‐
ity of MCM, N2a cells were seeded in 96‐well plates at a density of 
2	×	105 cells/mL for 24 hours in the growth media and then incu‐
bated in MCM for another 24 hours The cell viability of BMDMs or 
N2a cells was measured by using MTT assay according to the manu‐
facturer instructions and as described previously (Sigma‐Aldrich).7
2.5 | Statistical analyses
Results are expressed as mean ± standard deviation (SD) and analyzed 
using GraphPad Prism 6.0 (GraphPad Software). Data were compared 
by one‐way analysis of variance (ANOVA) among groups followed by 
F I G U R E  1   Altering the antibiotic properties of azithromycin does not decrease macrophage viability. Bone marrow‐derived macrophages 
(BMDMs)	were	isolated	from	adult	mice	and	were	treated	with	AZM,	AZM1,	AZM4,	AZM5,	and	AZM7	at	concentrations	of	1,	5,	25,	and	
125 μmol/L for 24 h Cell viability was measured by using MTT assay. AZM or AZM derivatives exhibited no cytotoxicity at any tested 
concentration as compared to unstimulated, nontreated BMDM control (dotted line). Moreover, AZM and AZM derivatives at 25 and/or 
125 μmol/L significantly increased proliferation of BMDMs as compared to unstimulated controls at *P < 0.05, **P < 0.01, ***P < 0.001. Data 
are mean ±SD and representative of three independent biological replicate experiments
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Dunnett's or Holmes‐Sidak multiple comparison tests. Differences 
were determined to be statistically significant at P	value	≤0.05.
3  | RESULTS
3.1 | Assessment of macrophage viability
We chose to use primary bone marrow‐derived macrophages (BMDMs) 
for our studies as BMDM responses in vitro are predictive of CNS 
macrophage response in vivo. When stimulated with LPS+IFN‐gamma), 
BMDMs model proinflammatory macrophages found in neuropatholo‐
gies.2,8,19 No doses of AZM or its derivatives were toxic to BMDMs 
when applied directly to the cells for 24 hours (Figure 1). Interestingly, 
this prolonged stimulation of BMDMs with high doses of AZM and its 
derivatives resulted in increased readouts on the MTT assay indicative of 
increased BMDM proliferation or increased metabolic activity (Figure 1). 
This effect was not as robust after 6 hours of stimulation (Figure S8), and 
therefore, a 6‐hr stimulation time point was used for subsequent assays.
F I G U R E  2   Nonantibiotic macrolides polarize proinflammatory macrophages to an anti‐inflammatory phenotype. BMDMs were 
polarized	to	be	M1	macrophages	by	stimulating	with	LPS	+INF-gamma.	AZM,	AZM1,	AZM4,	AZM5,	and	AZM7	were	coapplied	to	M1	
cells at concentrations of 1, 5, 25, and 125 μmol/L for 6 h Protein levels of IL‐12 (A) and IL‐10 (B) in cell culture medium were analyzed by 
ELISA and expressed as fold change over M1 of mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 vs M1. Data are representative of three 
independent biological replicate experiments. Each experiment was performed in triplicates per treatment group. (A) AZM and AZM 5 at the 
concentrations of 25 and 125 μmol/L	significantly	decreased	proinflammatory	cytokine	IL-12,	while	AZM	4	and	AZM	7	significantly	reduced	
IL‐12 level only at the concentration of 125 μmol/L. AZM 1 showed no effect in changing IL‐12 secretion. (B) The anti‐inflammatory cytokine 
IL‐10 level was significantly increased in M1 macrophages coincubated with AZM and AZM 5 at the concentrations of 25 and 125 μmol/L; 
while	AZM	1,	AZM	4,	and	AZM	7	significantly	increased	IL-10	expression	only	at	the	highest	tested	concentration	of	125	μmol/L (B)
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3.2 | Macrophage IL‐12/IL‐10 levels with derivatives
The relative expression of IL‐10 and IL‐12 is a defining feature of M1 
and M2 macrophages27 with M2 macrophages producing high levels 
of IL 10 and low levels of IL‐12. Conversely, M1 macrophages pro‐
duce substantial amounts of IL‐12 and minimal IL‐10. These cytokine 
profiles are also predictive of the neurotoxic potential of stimulated 
macrophages with toxic potential decreasing with increased IL‐10 
and reduced IL‐12 production.7,28 Similar to previous observations,6,7 
AZM reduced production of the proinflammatory cytokine, IL‐12, 
and elevated the secretion of the anti‐inflammatory cytokine IL‐10 in 
M1 macrophages in a dose‐dependent manner 6 hours after stimu‐
lation. Compared to M1‐stimulated macrophages, costimulation of 
M1 stimulant (LPS +IFN‐gamma) with either 25 or 125 μmol/L AZM 
significantly decreased IL‐12 (P < 0.01 and <0.001, respectively) and 
increased IL‐10 (P < 0.01 and <0.0001, respectively; Figure 2).
To determine the immunomodulatory properties of our azi‐
thromycin derivatives, we examined IL‐10 and IL‐12 production in 
BMDMs costimulated with derivatives and M1 stimulants (LPS + 
INF‐gamma). We detected significantly decreased IL‐12 produc‐
tion with 125 μmol/L cotreatment concentrations for derivatives 
4 (P	<	0.001)	 and	 7	 (P < 0.05) relative to M1 stimulation alone 
(Figure 2). Derivative 5 had significantly reduced IL‐12 production 
with 25 μmol/L (P < 0.01) and 125 μmol/L (P < 0.0001) concentra‐
tions. There was no significant effect on IL‐12 with derivative 1. We 
observed reciprocal significant increases in IL‐10 with all derivatives 
at the highest dose of 125 μmol/L (P < 0.05, Figure 2). In addition, 
the 25 μmol/L stimulation with derivative 5 significantly increased 
production of IL‐10 relative to M1 (P < 0.001; Figure 2). RT‐PCR 
analyses of select genes associated with M1 or M2 macrophage 
phenotypes (ie, IL‐6, IL‐1b, TNF‐a, and TGF‐b) demonstrated simi‐
lar immunomodulatory effects between AZM and derivatives 4 and 
7	(Figure	S9).	Collectively,	these	data	demonstrate	that	altering	the	
bacterial binding residues of AZM does not reduce its immunomod‐
ulatory properties with AZM5 having similar dose‐response proper‐
ties as the parent compound.
3.3 | Macrophage‐mediated neurotoxicity with 
derivatives
We previously reported that M1 supernatant, that is, macrophage‐
conditioned medium (MCM), is neurotoxic when applied to neuron 
cells and treatment of M1 macrophages with AZM significantly al‐
leviates this neurotoxic effect.2,7 Since we have observed similar ef‐
fects of M1 MCM on both primary neurons and the neuro2A cell 
line,2,7 we chose to evaluate the neurotoxic potential of AZM and 
derivatives using neuro2a (N2A) cells. Consistent with these previ‐
ous observations, M1 MCM significantly reduced N2A cell viability 
(P < 0.0001 vs N2A cells incubated with unstimulated/untreated 
MCM; Figure 3). MCM generated by BMDM costimulation with LPS 
+ INF‐gamma and AZM (25 and 125 μmol/L) significantly reversed 
the MCM toxicity (25 μmol/L P < 0.0001; 125 μmol/L P < 0.05 vs 
M1; Figure 3). Direct application of AZM on N2A cells had no effect 
on cell viability, and MCM isolated from BMDMs treated with AZM 
in the absence of M1 stimulants had no effect on neuron viability 
(Figure 3).
AZM5 was the most comparable to AZM in alleviating neuro‐
toxicity of M1‐stimulated BMDMs, with concentrations of 25 and 
F I G U R E  3   Nonantibiotic macrolides decrease the neurotoxic potential of proinflammatory macrophages. Neuron 2A (N2A) cells were 
incubated with MCM for 24 h MCM from M1 macrophages reduced neuron cell viability significantly as compared to control (N2a cells 
treated with MCM from unstimulated, nontreated BMDMs, dotted line), M1 vs Control at $$$$P < 0.0001). MCM from M1 macrophages 
coincubated	with	AZM	and/or	AZM	4,	AZM	5,	and	AZM	7	at	25	and/or	125	μmol/L restored neuron cell viability as compared to M1 MCM 
(*P < 0.05, P < 0.01, P < 0.0001 vs M1). Derivative AZM 1 exhibited no effect in modulating M1 MCM‐induced neurotoxicity. Data are 
mean ± SD and representative of three independent biological replicate experiments
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125 μmol/L both showing significant neuroprotective effects 
(P < 0.01 and P < 0.0001, respectively, vs M1). Derivatives AZM4 
and	 AZM7	 at	 the	 concentration	 of	 125	μmol/L also significantly 
attenuated the neurotoxic effect of M1 MCM (P < 0.0001 vs M1). 
Contrastingly, AZM1 did not significantly decrease M1 MCM‐in‐
duced neurotoxicity at any tested concentrations.
4  | DISCUSSION
In this study, we demonstrate the retention of immunomodulatory 
activity in AZM derivatives with altered sugar moieties using ourin 
vitro model of macrophage CNS inflammation. This model accu‐
rately predicts the macrophage/microglial response in the injured 
CNS.7,8,19,20 Specifically, we demonstrate that these derivatives, 
like the AZM parent compound, have no negative toxic effects on 
macrophage viability, retain the ability to polarize M1 macrophages 
toward the M2 phenotype as determined by IL‐10/12 cytokine pro‐
files, and are equally effective in reducing the neurotoxic effects 
of M1 macrophage supernatants on neuronal cultures. In these 
studies, the ability of the derivatives to shift IL‐10/12 cytokine 
profiles closely correlated with their ability to mitigate M1 super‐
natant toxicity to neurons. This supports our notion of utilizing 
IL‐10/12 cytokine profiles as an indicator of M1/M2 macrophage 
polarization and neurotoxicity. Recent literature demonstrates that 
AZM increases reparative macrophage activation in rodent mod‐
els of spinal cord injury, stroke, lung infection, skin inflammation, 
and in humans with cystic fibrosis.7-12,29-31 This anti‐inflammatory 
mechanism, potentially unrelated to AZM's antibacterial properties, 
holds great promise in the treatment of these diverse inflammatory 
conditions.
Further, this relatively unexplored therapeutic approach could 
likely be exploited more effectively with continued optimization 
of therapeutics such as AZM and related macrolides. In particular, 
one major obstacle in the clinical development of anti‐inflammatory 
macrolide antibiotics, such as AZM, is the concern that increased 
use of these drugs for their secondary anti‐inflammatory effects 
may inadvertently promote bacterial resistance to this antibiotic 
in the treatment of a variety of infections. In the spinal cord injury 
patient population, for example, AZM is the antibiotic of choice for 
treating recurrent respiratory infections and pneumonia,32 a leading 
cause of death following spinal cord injury; thus, antibiotic resis‐
tance is a major concern. Fortunately, recent studies have indicated 
that macrolides modified to remove their antibacterial activity retain 
beneficial anti‐inflammatory effects in models of inflammatory skin 
disorders and chronic lung diseases.13,16
Collectively, we demonstrate that AZM derivatives with al‐
tered sugar moieties retain immunomodulatory properties. We 
did not, however, observe uniform immunomodulatory and neu‐
roprotective	properties	with	all	derivatives	 tested.	AZM7,	which	
had the most extensive chemical modifications (diacetylation 
and the removal of the cladinose moiety), invoked modest immu‐
nomodulatory effects exclusively at the highest concentration 
tested.	Interestingly,	however,	AZM7	did	not	retain	any	antistaph‐
ylococcal activity. Similarly, AZM4, which also lacks the cladinose 
that is replaced by a carbonyl, had modest yet significant immu‐
nomodulatory effects with minimal antistaphylococcal activity. 
Although AZM1 at the concentration of 125 μmol/L significantly 
increases IL‐10 level, it has no effect in reducing IL‐12 production. 
Interestingly, AZM1 also induced significant but small changes, 
relative to AZM, in BMDM metabolic activity at this high dose. 
AZM5, which was the only derivative tested without the cladi‐
nose removed, closely mimicked or slightly exceeded AZM's ac‐
tivity at all concentrations tested including the BMDM MTT assay. 
Unfortunately, the acetylation of both sugars in AZM5 did not 
abolish the antistaphylococcal activity as desired. This may sug‐
gest, however, that chemical modifications to substitute the cla‐
dinose with functional variants may be an effective approach in 
developing subsequent generations of derivatives. Future studies 
that systematically alter each of these components may better 
clarify which of these modifications are beneficial or detrimental 
in retaining/improving AZM's immunomodulatory activity.
We demonstrated the clear anti‐inflammatory activity of these 
AZM derivativesin vitro; however, related studies utilizing derivatives 
of AZM and other macrolides suggest that these drug candidates likely 
hold great potential for treating inflammatory disorders of the CNS in 
vivo. For example, Sugawara et. al (2012) developed a series of anti‐in‐
flammatory nonantibiotic macrolide derivatives in vitro and then suc‐
cessfully used these derivatives in an in vivo model of inflammatory 
bowel disease.14 Together with our prior work demonstrating the pre‐
dictive nature of our in vitro model,7,8,19,20 these results suggest that 
our compounds hold great promise in treating the detrimental neuroin‐
flammatory conditions. Given that there are extremely few treatment 
options for most neurological disorders, our current findings clearly 
demonstrate the importance of these drugs and support their contin‐
ued development into novel therapeutics to treat CNS inflammation.
While the current study and related publications show encourag‐
ing therapeutic outcomes following stimulations with derivatives of 
AZM and other macrolides, the exact mechanisms of action remain 
uncertain. Much of the work in this regard has converged in identify‐
ing the NF‐κB signaling cascade as the core regulator of the observed 
shifts in cytokine profiles following macrolide treatment.29,33‐35 
While this is clearly important, the molecular target upstream of 
the NF‐κB cascade on which these drugs act remains unclear.36 In 
vitro studies show that AZM accumulates in macrophage lysosomes, 
where it increases the pH, interacts with membrane lipids, induces 
phospholipidosis, and alters vesicular trafficking which may affect 
endocytosis and phagocytosis.37,38 Other suggested mechanisms 
indicate that AZM may alter cellular autophagy, or alter the TLR4 
signaling pathways by changing endosome trafficking.37 Further, 
it remains unknown whether these findings remain valid in vivo 
or whether derivatives of AZM retain the same mechanism of ac‐
tion. While complicated, continued work in these areas is essential 
as it could lead to new therapeutics, such as the compounds de‐
scribed here, or provide novel therapeutic targets for future drug 
development.
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One interesting finding in the current study was the fairly pro‐
nounced increase in macrophage viability when treated with the high‐
est dose of AZM or derivative for 24 hours (widely used time point 
for measuring drug toxicity in vitro). This assay measures the conver‐
sion of tetrazolium dye MTT 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphen‐
yltetrazolium bromide to formazan by NAD(P)H‐dependent cellular 
oxidoreductase enzymes, and this measure of metabolic activity is 
routinely used to quantify changes in cell number or vitality. How AZM 
and its derivatives induce this effect at high concentrations, and how 
this may alter inflammatory activities remains unclear, however, it is 
unlikely that this is directly related to our observed shifts in cytokine 
profiles and neurotoxicity across drug concentrations. If the observed 
increases in IL‐10 following AZM stimulations were simply a result of 
cellular proliferation, then IL‐12 would also be expected to rise, instead, 
however, IL‐12 levels fell dramatically. Similarly, measurements of cel‐
lular proliferation/metabolism at the 6‐hour time point, when we mea‐
sure IL‐10/12 levels, displayed more modest increases in proliferation/
metabolism and are thus less likely to influence our cytokine profiles.
In conclusion, we have identified AZM derivatives that retain 
key immunomodulatory functions in our in vitro model of CNS 
inflammation. While the antiinfective properties of the deriva‐
tives were associated with neuroprotection, we also observed 
that some derivatives with greatly reduced antiinfective charac‐
teristics retained neuroprotective and anti‐inflammatory func‐
tions. Although a limited sample size of derivatives was created 
and tested, this indicates that the antibiotic properties of AZM 
may not be required for immunomodulatory‐mediated neuropro‐
tection. With continued development, these compounds could 
become viable clinical neuroprotectants and immunomodulatory 
treatments for neuropathologies. Additionally, given the usage 
of AZM's anti‐inflammatory properties across disciplines, these 
drugs hold great potential in treating a wide variety of inflamma‐
tion‐based human disorders.
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